Spotlight on Oncology

Credits: 1.0 CME / CNE / CPE
The Evolving Treatment Landscape for Higher-Risk Myelodysplastic Syndrome
Jamile M. Shammo, MD, FASCP, FACP
Rush University Medical Center

The Evolving Treatment Landscape for Higher-Risk Myelodysplastic Syndrome

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 3, 2022
Expires: June 2, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, hematologists/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with MDS.

Learning Objectives

After completing this program, participants should be able to:

  • Describe approaches for MDS diagnosis, classification, and risk stratification using hematologic, morphologic, clinical, and cytogenetic assessments
  • Outline available treatment approaches and associated outcomes for patients with MDS based on risk stratification, patient factors, clinical evidence, and available guidelines
  • Evaluate the clinical data regarding the efficacy and safety of emerging therapies for the treatment of patients with higher-risk MDS
  • Review factors that may impact consideration of clinical trial participation in patients with higher-risk MDS

Activity Description

Numerous new targeted therapies have emerged in recent years with early indications of benefit in patients with higher-risk MDS, particularly in combination with HMAs. These emerging options, which employ novel mechanisms of action and distinct molecular targets, may represent the first targeted therapies to improve outcomes in patients with higher-risk MDS. However, given the recent rapid emergence of data, clinicians are challenged to remain up to date on the latest evidence and the potential role of these therapies in the treatment landscape for patients with high-risk MDS. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application. Clinicians will hear up-to-date information on the latest evidence and the potential role of these therapies in the treatment landscape for patients with MDS.

Statement of Educational Need

With the recent advances in targeted therapies for higher-risk MDS, the use of investigational agents is anticipated to expand over the coming years. The introduction of these new agents and combinations into the clinic will likely change the therapeutic landscape for MDS and given the highly variable nature of the disease, will likely create uncertainty over differences in patients who may benefit, efficacy of emerging agents, optimal sequencing and combinations, and safety of the new agents and combinations. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with MDS, current evidence-based recommendations for the management of the disease, and the clinical utility of agents that could significantly impact patient outcomes.

Faculty

Jamile M. Shammo, MD, FASCP, FACP
Professor of Medicine and Pathology
Director of MDS/MPN/Aplastic Anemia Program
Rush University Medical Center
Chicago, IL

Dr. Shammo has provided the following disclosure information:
  • Research Grant: AbbVie, Alexion, AstraZeneca, CTI, Incyte, Kartos, Stemline, BMS
  • Stockholder: AbbVie, Takeda, Baxter
  • Member, Speakers Bureau: Sanofi, Incyte, Alexion, BMS
  • Other: DSMB for NS Pharma and Apellis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from AbbVie, Gilead Sciences, Inc. and Novartis Pharmaceuticals Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 3, 2022
Expires: June 2, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, hematologists/oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with MDS.

Learning Objectives

After completing this program, participants should be able to:

  • Describe approaches for MDS diagnosis, classification, and risk stratification using hematologic, morphologic, clinical, and cytogenetic assessments
  • Outline available treatment approaches and associated outcomes for patients with MDS based on risk stratification, patient factors, clinical evidence, and available guidelines
  • Evaluate the clinical data regarding the efficacy and safety of emerging therapies for the treatment of patients with higher-risk MDS
  • Review factors that may impact consideration of clinical trial participation in patients with higher-risk MDS

Activity Description

Numerous new targeted therapies have emerged in recent years with early indications of benefit in patients with higher-risk MDS, particularly in combination with HMAs. These emerging options, which employ novel mechanisms of action and distinct molecular targets, may represent the first targeted therapies to improve outcomes in patients with higher-risk MDS. However, given the recent rapid emergence of data, clinicians are challenged to remain up to date on the latest evidence and the potential role of these therapies in the treatment landscape for patients with high-risk MDS. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application. Clinicians will hear up-to-date information on the latest evidence and the potential role of these therapies in the treatment landscape for patients with MDS.

Statement of Educational Need

With the recent advances in targeted therapies for higher-risk MDS, the use of investigational agents is anticipated to expand over the coming years. The introduction of these new agents and combinations into the clinic will likely change the therapeutic landscape for MDS and given the highly variable nature of the disease, will likely create uncertainty over differences in patients who may benefit, efficacy of emerging agents, optimal sequencing and combinations, and safety of the new agents and combinations. To provide optimal patient care, clinicians must be prepared with a comprehensive understanding of the appropriate diagnosis and risk stratification of patients with MDS, current evidence-based recommendations for the management of the disease, and the clinical utility of agents that could significantly impact patient outcomes.

Faculty

Jamile M. Shammo, MD, FASCP, FACP
Professor of Medicine and Pathology
Director of MDS/MPN/Aplastic Anemia Program
Rush University Medical Center
Chicago, IL

Dr. Shammo has provided the following disclosure information:
  • Research Grant: AbbVie, Alexion, AstraZeneca, CTI, Incyte, Kartos, Stemline, BMS
  • Stockholder: AbbVie, Takeda, Baxter
  • Member, Speakers Bureau: Sanofi, Incyte, Alexion, BMS
  • Other: DSMB for NS Pharma and Apellis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from AbbVie, Gilead Sciences, Inc. and Novartis Pharmaceuticals Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Oncology Presentations

Miguel-Angel Perales, MD
1.0 CME / CNE / CPE
RMEI Medical Education, LLC
Taking Stock of the Evolving Treatment Landscape for Acute GvHD in HSCT: Proceedings from a Clinical Olympics℠

Taking Stock of the Evolving Treatment Landscape for Acute GvHD in HSCT: Proceedings from a Clinical Olympics℠

Start

Activity Details

Free CME/CPE/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ANCC Contact Hour(s)
1.0 ACPE Contact Hour(s)
Released: February 1, 2023
Expires: January 31, 2024
60 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Hematology, hematology/oncology, and transplantation clinicians

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Apply available therapies and guidelines for acute graft-versus-host disease (aGVHD) management in hematopoietic stem cell transplantation (HSCT) patients
  • Examine current data and ongoing clinical trials of emerging therapies for the management of acute GVHD in the allogeneic HSCT population

Activity Description

Allogeneic hematopoietic cell transplantation is a potentially curative therapy for many malignant and nonmalignant hematologic diseases. Acute graft-versus-host disease (aGVHD) is a common complication associated with this procedure that can affect up to 50% of patients. Patients with aGVHD commonly present with a maculopapular rash, nausea, vomiting, profuse watery diarrhea and abdominal cramping, and hyperbilirubinemia with jaundice. In this educational activity, renowned GVHD experts discuss staging/grading of GVHD, current prophylactic and treatment strategies, and emerging agents.

Chair

Miguel-Angel Perales, MD
Chief, Adult Bone Marrow Transplantation Service
Memorial Sloan Kettering Cancer Center
Associate Professor, Medicine
Weill Cornell Medical College
New York, NY

Faculty

Nelson J. Chao, MD, MBA
Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematologic Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, NC

Sung Won Choi, MD, MS
Professor, Pediatrics
Hematology/Oncology
Edith S Briskin and Shirley K Schlafer Research Professor
Blood and Marrow Transplantation Program
University of Michigan
Ann Arbor, MI


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. 

Faculty

Nelson J. Chao, MD, MBA, has no relevant financial relationship(s) with ineligible companies to disclose. 

Sung WonChoi, MD, MS, has no relevant financial relationship(s) with ineligible companies to disclose. 
 
Miguel-AngelPerales, MD, has relevant financial relationships with AbbVie, AlloVir, Astellas, Bristol Myers Squibb, Celgene, Cidara Therapeutics, Inc., Equillium, ExeVir, Incyte, Karyopharm Therapeutics Inc, Kite/Gilead, Medigene, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, NexImmune, Novartis, Omeros, Orca Bio, Sellas Life Sciences, Servier, Takeda, VectivBio AG, Vor Biopharma (Advisor).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers 
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education  
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008290-0000-23-001-H01-P)
Type of Activity: Knowledge

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the challenge questions to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:  

  • Read the learning objectives and faculty disclosures 
  • Participate in the activity 
  • Complete the activity evaluation and attest to credit    

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. 

Statement of Commercial Support

This activity is supported by an independent educational grant from CSL Behring LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CPE/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ANCC Contact Hour(s)
1.0 ACPE Contact Hour(s)
Released: February 1, 2023
Expires: January 31, 2024
60 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Hematology, hematology/oncology, and transplantation clinicians

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Apply available therapies and guidelines for acute graft-versus-host disease (aGVHD) management in hematopoietic stem cell transplantation (HSCT) patients
  • Examine current data and ongoing clinical trials of emerging therapies for the management of acute GVHD in the allogeneic HSCT population

Activity Description

Allogeneic hematopoietic cell transplantation is a potentially curative therapy for many malignant and nonmalignant hematologic diseases. Acute graft-versus-host disease (aGVHD) is a common complication associated with this procedure that can affect up to 50% of patients. Patients with aGVHD commonly present with a maculopapular rash, nausea, vomiting, profuse watery diarrhea and abdominal cramping, and hyperbilirubinemia with jaundice. In this educational activity, renowned GVHD experts discuss staging/grading of GVHD, current prophylactic and treatment strategies, and emerging agents.

Chair

Miguel-Angel Perales, MD
Chief, Adult Bone Marrow Transplantation Service
Memorial Sloan Kettering Cancer Center
Associate Professor, Medicine
Weill Cornell Medical College
New York, NY

Faculty

Nelson J. Chao, MD, MBA
Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematologic Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, NC

Sung Won Choi, MD, MS
Professor, Pediatrics
Hematology/Oncology
Edith S Briskin and Shirley K Schlafer Research Professor
Blood and Marrow Transplantation Program
University of Michigan
Ann Arbor, MI


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. 

Faculty

Nelson J. Chao, MD, MBA, has no relevant financial relationship(s) with ineligible companies to disclose. 

Sung WonChoi, MD, MS, has no relevant financial relationship(s) with ineligible companies to disclose. 
 
Miguel-AngelPerales, MD, has relevant financial relationships with AbbVie, AlloVir, Astellas, Bristol Myers Squibb, Celgene, Cidara Therapeutics, Inc., Equillium, ExeVir, Incyte, Karyopharm Therapeutics Inc, Kite/Gilead, Medigene, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, NexImmune, Novartis, Omeros, Orca Bio, Sellas Life Sciences, Servier, Takeda, VectivBio AG, Vor Biopharma (Advisor).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers 
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education  
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008290-0000-23-001-H01-P)
Type of Activity: Knowledge

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the challenge questions to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:  

  • Read the learning objectives and faculty disclosures 
  • Participate in the activity 
  • Complete the activity evaluation and attest to credit    

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card. 

Statement of Commercial Support

This activity is supported by an independent educational grant from CSL Behring LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Sundar Jagannath, MD, FASCO
1.0 CME / CNE
RMEI Medical Education, LLC
Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/Refractory Disease? Proceedings from a Clinical Olympics℠

Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/Refractory Disease? Proceedings from a Clinical Olympics℠

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ANCC Contact Hour(s)
Released: January 30, 2023
Expires: January 29, 2024
60 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Medical oncologists, hematologists, hematologist-oncologists, pathologists, and oncology nurses

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select an appropriate B cell maturation antigen (BCMA) targeted therapy among approved options for patients with relapsed/refractory (R/R) multiple myeloma (MM)
  • Integrate novel BCMA-targeted therapies into the treatment paradigm of R/R MM, with an emphasis on bispecific antibodies
  • Manage adverse events (AEs) associated with BCMA-directed therapies in patients with R/R MM

Activity Description

The advent of BCMA-directed therapy fills a significant gap in the treatment of relapsed/refractory multiple myeloma. As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Sundar Jagannath, Dr. María-Victoria Mateos, and Dr. James Hoffman provide privileged insights into optimal selection and integration of BCMA-directed therapies, particularly bispecific antibodies, to maximize patient outcomes.

Chair

Sundar Jagannath, MD, FASCO
Chair, Multiple Myeloma
Professor, Medicine
Icahn School of Medicine at Mount Sinai
Director, Multiple Myeloma Center of Excellence
Tisch Cancer Center Institute
Editor-in-Chief, Clinical Lymphoma, Myeloma & Leukemia
Mount Sinai Hospital
New York, NY


Faculty

James Hoffman, MD
Associate Professor, Clinical Medicine
Division of Myeloma (Hematology)
Sylvester Comprehensive Cancer Center (SCCC)
University of Miami
Miami, FL


María-Victoria Mateos, MD, PhD
Associate Professor, Hematology
Director, Myeloma Program
University Hospital of Salamanca
Salamanca, Spain

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

James Hoffman, MD, has relevant financial relationships with Bristol Myers Squibb (Speaker/Speaker’s Bureau).

Sundar Jagannath, MD, FASCO, has relevant financial relationships with Epizyme, Karyopharm Therapeutics (Advisor); Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Legend Biotech, Sanofi (Consultant).

María-Victoria Mateos, MD, PhD, has relevant financial relationships with Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Oncopeptides, Inc., Pfizer, Sanofi, Seagen, Inc. (Advisor); Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Pfizer, Sanofi, Takeda (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies. 

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose with the exception of Sara Fagerlie, PhD, CHCP, medical writer, who had a relevant financial relationship with Adaptive Biotechnologies (Consultant). This relevant financial relationship has been divested.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at Accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ANCC Contact Hour(s)
Released: January 30, 2023
Expires: January 29, 2024
60 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Medical oncologists, hematologists, hematologist-oncologists, pathologists, and oncology nurses

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Select an appropriate B cell maturation antigen (BCMA) targeted therapy among approved options for patients with relapsed/refractory (R/R) multiple myeloma (MM)
  • Integrate novel BCMA-targeted therapies into the treatment paradigm of R/R MM, with an emphasis on bispecific antibodies
  • Manage adverse events (AEs) associated with BCMA-directed therapies in patients with R/R MM

Activity Description

The advent of BCMA-directed therapy fills a significant gap in the treatment of relapsed/refractory multiple myeloma. As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Sundar Jagannath, Dr. María-Victoria Mateos, and Dr. James Hoffman provide privileged insights into optimal selection and integration of BCMA-directed therapies, particularly bispecific antibodies, to maximize patient outcomes.

Chair

Sundar Jagannath, MD, FASCO
Chair, Multiple Myeloma
Professor, Medicine
Icahn School of Medicine at Mount Sinai
Director, Multiple Myeloma Center of Excellence
Tisch Cancer Center Institute
Editor-in-Chief, Clinical Lymphoma, Myeloma & Leukemia
Mount Sinai Hospital
New York, NY


Faculty

James Hoffman, MD
Associate Professor, Clinical Medicine
Division of Myeloma (Hematology)
Sylvester Comprehensive Cancer Center (SCCC)
University of Miami
Miami, FL


María-Victoria Mateos, MD, PhD
Associate Professor, Hematology
Director, Myeloma Program
University Hospital of Salamanca
Salamanca, Spain

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

James Hoffman, MD, has relevant financial relationships with Bristol Myers Squibb (Speaker/Speaker’s Bureau).

Sundar Jagannath, MD, FASCO, has relevant financial relationships with Epizyme, Karyopharm Therapeutics (Advisor); Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Legend Biotech, Sanofi (Consultant).

María-Victoria Mateos, MD, PhD, has relevant financial relationships with Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Oncopeptides, Inc., Pfizer, Sanofi, Seagen, Inc. (Advisor); Amgen, Bristol Myers Squibb, GSK, Janssen Pharmaceuticals, Pfizer, Sanofi, Takeda (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies. 

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose with the exception of Sara Fagerlie, PhD, CHCP, medical writer, who had a relevant financial relationship with Adaptive Biotechnologies (Consultant). This relevant financial relationship has been divested.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at Accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Jared M. Weiss, MD
1.0 CME / CNE
RMEI Medical Education, LLC
Harnessing the Full Potential of Frontline Immunotherapy in Advanced NSCLC: Proceedings from a Clinical Olympics℠

Harnessing the Full Potential of Frontline Immunotherapy in Advanced NSCLC: Proceedings from a Clinical Olympics℠

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ANCC Contact Hour(s)
Released: September 29, 2022
Expires: September 28, 2023
60 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Medical oncology and pulmonology clinicians managing patients with advanced NSCLC.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Utilize molecular testing in patients with advanced non-small cell lung cancer (NSCLC) as a guide for frontline treatment selection
  • Select optimal frontline immune checkpoint inhibitor regimens in appropriate patients with advanced NSCLC
  • Manage potential immune-related adverse events in patients with advanced NSCLC receiving first-line immunotherapy

Activity Description

The advent of frontline immunotherapy has significantly extended survival for certain patients with metastatic non-small cell lung cancer (NSCLC). As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Jared Weiss, Prof. Aleš Ryška, and Dr. Mihaela Aldea provide privileged insights into the nuances of biomarker testing, optimal regimen selection, and management of immune-related adverse events.

Faculty

Jared M. Weiss, MD
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, United States


Prof. MUDr. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology
Charles University Medical Faculty
Hradec Králové University Hospital
Prague, Czech Republic


Mihaela Aldea, MD, PhD
Associate Professor, Medical Oncology
Paris-Saclay University
Gustave Roussy
Villejuif, France

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Jared M. Weiss, MD, has relevant financial relationships with AstraZeneca, Boehringer Ingelheim, Eli Lilly, G1 Therapeutics, Merck, Mirati, Sumitomo Dainippon Pharma (Researcher); AbbVie, AstraZeneca, Azira, Eli Lilly, EMD Serono, G1 Therapeutics, Genentech, Genmab, Jazz Pharmaceuticals, Jounce Therapeutics, Nanobiotix, Pfizer, Regeneron, Sumitomo Dainippon Pharma (Consultant); Achilles, En Fuego Therapeutics, Lyell, Nuvalent, Vesselon (Stock/Stockholder).

Prof. MUDr. Aleš Ryška, MD, PhD, has relevant financial relationships with Amgen, Elphogene, Lilly, MSD, Roche (Advisor); Amgen, Bristol-Myers Squibb, Gilead, MSD, Roche (Speaker/Speaker’s Bureau); Roche, Sanofi (Other: Travel Support).

Mihaela Aldea, MD, PhD, has a relevant financial relationship with Sandoz (Other: Travel/Expenses).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 ANCC Contact Hour(s)
Released: September 29, 2022
Expires: September 28, 2023
60 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Medical oncology and pulmonology clinicians managing patients with advanced NSCLC.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Utilize molecular testing in patients with advanced non-small cell lung cancer (NSCLC) as a guide for frontline treatment selection
  • Select optimal frontline immune checkpoint inhibitor regimens in appropriate patients with advanced NSCLC
  • Manage potential immune-related adverse events in patients with advanced NSCLC receiving first-line immunotherapy

Activity Description

The advent of frontline immunotherapy has significantly extended survival for certain patients with metastatic non-small cell lung cancer (NSCLC). As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Jared Weiss, Prof. Aleš Ryška, and Dr. Mihaela Aldea provide privileged insights into the nuances of biomarker testing, optimal regimen selection, and management of immune-related adverse events.

Faculty

Jared M. Weiss, MD
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, United States


Prof. MUDr. Aleš Ryška, MD, PhD
Head, Fingerland Department of Pathology
Charles University Medical Faculty
Hradec Králové University Hospital
Prague, Czech Republic


Mihaela Aldea, MD, PhD
Associate Professor, Medical Oncology
Paris-Saclay University
Gustave Roussy
Villejuif, France

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Jared M. Weiss, MD, has relevant financial relationships with AstraZeneca, Boehringer Ingelheim, Eli Lilly, G1 Therapeutics, Merck, Mirati, Sumitomo Dainippon Pharma (Researcher); AbbVie, AstraZeneca, Azira, Eli Lilly, EMD Serono, G1 Therapeutics, Genentech, Genmab, Jazz Pharmaceuticals, Jounce Therapeutics, Nanobiotix, Pfizer, Regeneron, Sumitomo Dainippon Pharma (Consultant); Achilles, En Fuego Therapeutics, Lyell, Nuvalent, Vesselon (Stock/Stockholder).

Prof. MUDr. Aleš Ryška, MD, PhD, has relevant financial relationships with Amgen, Elphogene, Lilly, MSD, Roche (Advisor); Amgen, Bristol-Myers Squibb, Gilead, MSD, Roche (Speaker/Speaker’s Bureau); Roche, Sanofi (Other: Travel Support).

Mihaela Aldea, MD, PhD, has a relevant financial relationship with Sandoz (Other: Travel/Expenses).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Doris M. Ponce, MD
0.5 CME
RMEI Medical Education, LLC
Current and Emerging Therapies for Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Current and Emerging Therapies for Acute Graft-vs-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: September 23, 2022
Expires: September 22, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
  • Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT

Activity Description

Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.

Faculty

Doris M. Ponce, MD
Associate Professor, Medicine
Hematology/Oncology
Memorial Sloan Kettering Cancer Center
New York, NY


Christine N. Duncan, MD
Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).

Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from CSL Behring LLC.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: September 23, 2022
Expires: September 22, 2023
30 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

Transplantation, hematology, and hematology/oncology clinicians engaged in the care of patients with GVHD.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Utilize available therapeutic strategies for the prevention and treatment of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT)
  • Implement current and emerging strategies to address unmet needs in the management of steroid-refractory acute GVHD in allogeneic HSCT

Activity Description

Allogeneic HSCT is a revolutionary therapeutic discovery, yet despite advances, the procedure still carries substantial risk for complications and death. Even with prophylactic measures, many patients will go on to develop acute graft-versus-host disease (aGVHD). While there are several agents available for the prevention and treatment of aGVHD, there are still many unmet needs. In this Clinical Reflections® activity, learners will be presented with 2 cases of aGVHD and challenged by expert faculty to reflect back on how they could have been better managed. Faculty will then discuss current guidelines; prevention and treatment options; and emerging agents for prevention, first-line therapy, and steroid-refractory aGVHD.

Faculty

Doris M. Ponce, MD
Associate Professor, Medicine
Hematology/Oncology
Memorial Sloan Kettering Cancer Center
New York, NY


Christine N. Duncan, MD
Assistant Professor, Pediatrics
Harvard Medical School
Medical Director, Clinical Research and Clinical Development
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, MA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Christine N. Duncan, MD, has relevant financial relationships with bluebird bio, Inc., Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Omeros, Tome Biosciences (Consultant).

Doris M. Ponce, MD, has relevant financial relationships with Incyte Corporation, Kadmon Corporation (Advisor); CareDx, Ceramedix, Evive Biotech, Kadmon Corporation (Consultant); Incyte Corporation (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 67% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

There is no fee to participate.

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from CSL Behring LLC.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

1.0 CME / CNE / CPE
Rush University Medical Center
Advances in Cervical Cancer: Addressing Unmet Needs in an Evolving Therapeutic Landscape

Advances in Cervical Cancer: Addressing Unmet Needs in an Evolving Therapeutic Landscape

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 14, 2022
Expires: July 13, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, gynecologic oncologists, oncology nurses, NPs/PAs, pharmacists and other healthcare professionals involved in the treatment of patients with cervical cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Assess clinical trial data of newly approved and emerging investigational agents for the treatment of recurrent or metastatic cervical cancer, and their potential role in the context of existing treatment paradigms
  • Integrate novel therapies into treatment plans for patients with recurrent or metastatic cervical cancer based on available guidelines, clinical trial data, and sequencing considerations
  • Identify and manage adverse events (AEs) associated with novel agents to promote adherence to therapy and optimize patient care
  • Incorporate multidisciplinary strategies into current clinical practice to provide best possible care of patients with recurrent or metastatic cervical cancer

Activity Description

This education activity is designed to provide the health-care team with the latest developments and critical insights into the treatment of recurrent or metastatic cervical cancer. This education will support the health-care professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

To provide optimal care to patients with recurrent or metastatic cervical cancer, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact patient outcomes. New and emerging therapies have significantly modified the treatment landscape in recurrent or metastatic cervical cancer. Due to the overwhelming amount of data that have been released in recent years, clinicians require education on the most relevant information, as well as identifying and managing treatment-related AEs, that will enable them to significantly enhance patient outcomes.

Faculty

Robert L. Coleman, M.D., FACOG, FACS
Gynecology/Oncology
US Oncology Research
Texas Oncology
Texas, United States

Disclosure
  • Scientific Steering Committee: AbbVie, AstraZeneca, Clovis Oncology, Genmab/Seagen, Immunogen, Janssen, Merck, Pfizer, Roche/Genentech, GSK, Deciphera, Zentalis, Alkermes, Agenus, Karyopharm, Mersana, Gradalis, Epsilogen
  • Research Funding: AstraZeneca, Abbvie, Clovis Oncology, Genmab/Seagen, Merck, Novartis, Roche/Genentech, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this Enduring Activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/ Physician Assistants/ Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this Enduring Activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Seagen and Genmab.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: July 14, 2022
Expires: July 13, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of community oncologists, gynecologic oncologists, oncology nurses, NPs/PAs, pharmacists and other healthcare professionals involved in the treatment of patients with cervical cancer.

Learning Objectives

After completing this program, participants should be able to:

  • Assess clinical trial data of newly approved and emerging investigational agents for the treatment of recurrent or metastatic cervical cancer, and their potential role in the context of existing treatment paradigms
  • Integrate novel therapies into treatment plans for patients with recurrent or metastatic cervical cancer based on available guidelines, clinical trial data, and sequencing considerations
  • Identify and manage adverse events (AEs) associated with novel agents to promote adherence to therapy and optimize patient care
  • Incorporate multidisciplinary strategies into current clinical practice to provide best possible care of patients with recurrent or metastatic cervical cancer

Activity Description

This education activity is designed to provide the health-care team with the latest developments and critical insights into the treatment of recurrent or metastatic cervical cancer. This education will support the health-care professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application.

Statement of Educational Need

To provide optimal care to patients with recurrent or metastatic cervical cancer, clinicians must be prepared with a comprehensive understanding of the clinical utility of agents that could significantly impact patient outcomes. New and emerging therapies have significantly modified the treatment landscape in recurrent or metastatic cervical cancer. Due to the overwhelming amount of data that have been released in recent years, clinicians require education on the most relevant information, as well as identifying and managing treatment-related AEs, that will enable them to significantly enhance patient outcomes.

Faculty

Robert L. Coleman, M.D., FACOG, FACS
Gynecology/Oncology
US Oncology Research
Texas Oncology
Texas, United States

Disclosure
  • Scientific Steering Committee: AbbVie, AstraZeneca, Clovis Oncology, Genmab/Seagen, Immunogen, Janssen, Merck, Pfizer, Roche/Genentech, GSK, Deciphera, Zentalis, Alkermes, Agenus, Karyopharm, Mersana, Gradalis, Epsilogen
  • Research Funding: AstraZeneca, Abbvie, Clovis Oncology, Genmab/Seagen, Merck, Novartis, Roche/Genentech, Zentalis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this Enduring Activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/ Physician Assistants/ Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University designates this Enduring Activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by an educational grant from Seagen and Genmab.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Martina C. Murphy, MD
1.0 CME
Integrity Continuing Education, Inc.
Contemporary Treatment of Endometrial Cancer: An In The Clinic Activity

Contemporary Treatment of Endometrial Cancer: An In The Clinic Activity

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 30, 2022
Expires: June 30, 2023
60 minutes to complete

Provided By

Integrity Continuing Education, Inc.

Statement of Commercial Support

This educational activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This educational activity has been designed to meet the needs of medical and gynecologic oncologists, physician assistants, and nurse practitioners who treat and manage patients with gynecologic malignancies, with a focus on the community-based clinician.

Activity Description

The treatment options for advanced or recurrent endometrial cancer (EC) have changed dramatically in the last five years. Molecular testing to identify patients that could benefit from targeted treatments is now recommended for all patients. Choosing the optimal treatment can be complex as treatment planning must consider molecular signatures, safety and efficacy data, patient and tumor characteristics, and guideline recommendations.

In this edition of In the Clinic, Drs. Murphy and Westin will unpack the latest clinical trial data and review best practices for approaching treatment for these patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Elucidate the necessity for genetic and molecular testing to aid in selecting appropriate monotherapeutic or combination treatment options to improve survival outcomes in patients with advanced or recurrent EC
  • Devise a strategy to incorporate recently approved or emerging treatment options for patients with advanced or recurrent EC based on clinical trial findings
  • Identify and monitor for, as well as manage and mitigate against, adverse reactions that can be caused by treatments that were recently approved for advanced or recurrent EC

Faculty Co-Chairs

Martina C. Murphy, MD
Associate Professor of Medicine
Director, UFCOM Introduction to Clinical Medicine 1A & 1B
Program Director
Hematology/Oncology Fellowship
University of Florida
Gainesville, Florida

Martina C. Murphy, MD, does not have any real or apparent conflicts to disclose.


Shannon N. Westin, MD, MPH
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Contracts: AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis
Consulting Fees: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis

Case Development Faculty

Michaela Onstad-Grinsfelder, MD, MPH
Assistant Professor
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Michaela Onstad-Grinsfelder, MD, MPH, does not have any real or apparent conflicts to disclose.

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2022 through June 30, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 30, 2022
Expires: June 30, 2023
60 minutes to complete

Provided By

Integrity Continuing Education, Inc.

Statement of Commercial Support

This educational activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This educational activity has been designed to meet the needs of medical and gynecologic oncologists, physician assistants, and nurse practitioners who treat and manage patients with gynecologic malignancies, with a focus on the community-based clinician.

Activity Description

The treatment options for advanced or recurrent endometrial cancer (EC) have changed dramatically in the last five years. Molecular testing to identify patients that could benefit from targeted treatments is now recommended for all patients. Choosing the optimal treatment can be complex as treatment planning must consider molecular signatures, safety and efficacy data, patient and tumor characteristics, and guideline recommendations.

In this edition of In the Clinic, Drs. Murphy and Westin will unpack the latest clinical trial data and review best practices for approaching treatment for these patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Elucidate the necessity for genetic and molecular testing to aid in selecting appropriate monotherapeutic or combination treatment options to improve survival outcomes in patients with advanced or recurrent EC
  • Devise a strategy to incorporate recently approved or emerging treatment options for patients with advanced or recurrent EC based on clinical trial findings
  • Identify and monitor for, as well as manage and mitigate against, adverse reactions that can be caused by treatments that were recently approved for advanced or recurrent EC

Faculty Co-Chairs

Martina C. Murphy, MD
Associate Professor of Medicine
Director, UFCOM Introduction to Clinical Medicine 1A & 1B
Program Director
Hematology/Oncology Fellowship
University of Florida
Gainesville, Florida

Martina C. Murphy, MD, does not have any real or apparent conflicts to disclose.


Shannon N. Westin, MD, MPH
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Contracts: AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis
Consulting Fees: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis

Case Development Faculty

Michaela Onstad-Grinsfelder, MD, MPH
Assistant Professor
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Michaela Onstad-Grinsfelder, MD, MPH, does not have any real or apparent conflicts to disclose.

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2022 through June 30, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

1.0 CME / CNE / CPE
Rush University Medical Center
Optimizing Care of Veterans with Advanced Renal Cell Carcinoma: Incorporating Immunotherapies and Targeted Agents into Clinical Practice

Optimizing Care of Veterans with Advanced Renal Cell Carcinoma: Incorporating Immunotherapies and Targeted Agents into Clinical Practice

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 16, 2022
Expires: June 15, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with renal cell carcinoma.

Learning Objectives

After completing this program, participants should be able to:

  • Analyze recent clinical trial data regarding the efficacy and safety of first-line immunotherapy-containing regimens for advanced renal cell carcinoma (RCC).
  • Identify and manage immune-related adverse events (irAEs) associated with immunotherapy-containing regimens.
  • Assess the appropriate roles for new therapies in the current treatment landscape of relapsed or refractory advanced RCC in the veteran population.
  • Integrate new therapeutic approaches into treatment plans for veterans with RCC within the VHA/MHS/DoD healthcare system.

Activity Description

This educational activity is designed to provide the healthcare team with the latest developments and critical insights into the management of advanced renal cell carcinoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application of available therapies.

Statement of Educational Need

The treatment paradigm for advanced RCC has evolved rapidly in recent years with the arrival of next-generation TKIs and combination approaches with immune checkpoint inhibitors. Despite these advancements, patients continue to exhibit inferior outcomes. To provide optimal patient care, clinicians require in-depth education surrounding these novel treatments, including the most recent clinical data regarding the efficacy and safety of these agents, current guideline recommendations, appropriate management of potential AEs, and approaches to select among available options and combinations in the first-line setting and beyond for patients with advanced RCC. Therefore, clinician education is urgently needed to improve outcomes for patients with RCC.

Faculty

Matthew Rettig, MD
Professor of Medicine and Urology
David Geffen School of Medicine at UCLA
Chief, Division of Hematology-Oncology, VA GLAHS
Los Angeles, CA

Disclosure
  • Research Grant: Novartis, Johnson & Johnson, Merck, Astellas, Medivation
  • Member, Speakers Bureau: J&J, Bayer
  • Consultant: Amgen, Ambryx, Clovis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Eisai, Exelixis, and Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 16, 2022
Expires: June 15, 2023
60 minutes to complete

Accredited By

Rush University Medical Center

Co-Provided By

Target Audience

This activity is designed to meet the educational needs of oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with renal cell carcinoma.

Learning Objectives

After completing this program, participants should be able to:

  • Analyze recent clinical trial data regarding the efficacy and safety of first-line immunotherapy-containing regimens for advanced renal cell carcinoma (RCC).
  • Identify and manage immune-related adverse events (irAEs) associated with immunotherapy-containing regimens.
  • Assess the appropriate roles for new therapies in the current treatment landscape of relapsed or refractory advanced RCC in the veteran population.
  • Integrate new therapeutic approaches into treatment plans for veterans with RCC within the VHA/MHS/DoD healthcare system.

Activity Description

This educational activity is designed to provide the healthcare team with the latest developments and critical insights into the management of advanced renal cell carcinoma. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness, and application of available therapies.

Statement of Educational Need

The treatment paradigm for advanced RCC has evolved rapidly in recent years with the arrival of next-generation TKIs and combination approaches with immune checkpoint inhibitors. Despite these advancements, patients continue to exhibit inferior outcomes. To provide optimal patient care, clinicians require in-depth education surrounding these novel treatments, including the most recent clinical data regarding the efficacy and safety of these agents, current guideline recommendations, appropriate management of potential AEs, and approaches to select among available options and combinations in the first-line setting and beyond for patients with advanced RCC. Therefore, clinician education is urgently needed to improve outcomes for patients with RCC.

Faculty

Matthew Rettig, MD
Professor of Medicine and Urology
David Geffen School of Medicine at UCLA
Chief, Division of Hematology-Oncology, VA GLAHS
Los Angeles, CA

Disclosure
  • Research Grant: Novartis, Johnson & Johnson, Merck, Astellas, Medivation
  • Member, Speakers Bureau: J&J, Bayer
  • Consultant: Amgen, Ambryx, Clovis

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician/Physician Assistant/Nurse Practitioner
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) AMA PRA Category 1 Credit(s)™. Physicians/Physician Assistants/Nurse Practitioners should claim only credit commensurate with the extent of their participation in the activity.

Nurse
Rush University Medical Center designates this enduring activity for a maximum of one (1.0) nursing contact hour(s).

This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.

Pharmacist
Rush University Medical Center designates this knowledge-based enduring activity for a maximum of one (1.0) contact hour(s) for pharmacists.

Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.

Instructions for Receiving Credit

In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.

Statement of Commercial Support

This activity is supported by educational grants from AVEO Pharmaceuticals, Inc., Eisai, Exelixis, and Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

Rush University Medical Center and PleXus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University Medical Center identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University Medical Center to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University Medical Center is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

Contact Information for Questions About the Activity

info@plexuscomm.com

1.0 CME
RMEI Medical Education, LLC
Seeing Nonmelanoma Skin Cancers Through a New Lens: The Role and Place of Immunotherapy: A Care Team Forum®

Seeing Nonmelanoma Skin Cancers Through a New Lens: The Role and Place of Immunotherapy: A Care Team Forum®

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: June 14, 2022
Expires: June 13, 2023
60 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncology and dermatology clinicians who manage patients with nonmelanoma skin cancer (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with difficult-to-treat nonmelanoma skin cancer (NMSC) based on current staging systems, risk factors, and guidelines
  • Select appropriate immunotherapy for advanced NMSC based on available data and approved indications

Activity Description

Join our multidisciplinary experts for an interactive program offering privileged insights into the evolving nonmelanoma skin cancer (NMSC) treatment paradigm. Core topics include evidence-based strategies for identifying patients at increased risk for disease progression, pinpointing the evolution of advanced disease, and integrating immunotherapy as a key component of the armamentarium against advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). A patient panelist augments these insights by highlighting aspects of their own treatment journey.

Chair

Prof. Axel Hauschild, MD
Professor, Dermatology
Head of Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany

Faculty

David M. Miller, MD, PhD, FAAD
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Mass General Cancer Center
Boston, United States


Vishal Anil Patel, MD, FAAD, FACMS
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
George Washington University School of Medicine & Health Sciences
Washington DC, United States

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Prof. Axel Hauschild, MD, has relevant financial relationships with Amgen, BMS, Merck/Pfizer, MSD/Merck, Novartis, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme (Grant/Research Support).

David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Consultant); Checkpoint Therapeutics (Equity); Kartos Therapeutics, NeoImmune Tech, Inc, Regeneron (Research).

Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Almirall, Castle Biosciences, Regeneron, Sanofi (Speaker/Speaker’s Bureau); Jounce Therapeutics, PHD Biosciences, (Consultant); Almirall (Advisor); Lazarus AI, Science 37, Inc. (Stock/Shareholder).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: June 14, 2022
Expires: June 13, 2023
60 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for medical oncology and dermatology clinicians who manage patients with nonmelanoma skin cancer (NMSC).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with difficult-to-treat nonmelanoma skin cancer (NMSC) based on current staging systems, risk factors, and guidelines
  • Select appropriate immunotherapy for advanced NMSC based on available data and approved indications

Activity Description

Join our multidisciplinary experts for an interactive program offering privileged insights into the evolving nonmelanoma skin cancer (NMSC) treatment paradigm. Core topics include evidence-based strategies for identifying patients at increased risk for disease progression, pinpointing the evolution of advanced disease, and integrating immunotherapy as a key component of the armamentarium against advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). A patient panelist augments these insights by highlighting aspects of their own treatment journey.

Chair

Prof. Axel Hauschild, MD
Professor, Dermatology
Head of Dermato-oncology
Department of Dermatology
University of Kiel
Kiel, Germany

Faculty

David M. Miller, MD, PhD, FAAD
Medical Oncologist, Dermatologist
Massachusetts General Hospital
Director, Center for Merkel Cell Carcinoma
Co-Director, NMSC Multi-Disciplinary Clinic
Department of Medicine, Division of Hematology/Oncology
Department of Dermatology
Mass General Cancer Center
Boston, United States


Vishal Anil Patel, MD, FAAD, FACMS
Director, Cutaneous Oncology, GW Cancer Center
Director, Dermatologic Surgery, GW Department of Dermatology
Assistant Professor, Dermatology & Hematology/Oncology
George Washington University School of Medicine & Health Sciences
Washington DC, United States

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Prof. Axel Hauschild, MD, has relevant financial relationships with Amgen, BMS, Merck/Pfizer, MSD/Merck, Novartis, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme (Grant/Research Support).

David M. Miller, MD, PhD, FAAD, has relevant financial relationships with Castle Biosciences, Checkpoint Therapeutics, EMD Serono, Merck KGaA, Merck Sharpe & Dome, Pfizer, Regeneron, Sanofi Genzyme (Consultant); Checkpoint Therapeutics (Equity); Kartos Therapeutics, NeoImmune Tech, Inc, Regeneron (Research).

Vishal Anil Patel, MD, FAAD, FACMS, has relevant financial relationships with Almirall, Castle Biosciences, Regeneron, Sanofi (Speaker/Speaker’s Bureau); Jounce Therapeutics, PHD Biosciences, (Consultant); Almirall (Advisor); Lazarus AI, Science 37, Inc. (Stock/Shareholder).

Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.